Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
Marconi G, De Polo S, Martinelli G, Nanni J, Bertamini L, Talami A, Olivi M, Ragaini S, Abbenante MC, Sartor C, Ottaviani E, Bochicchio MT, Parisi S, Fontana MC, Cristiano G, Raffini M, Baldazzi C, Testoni N, Bonifazi F, Paolini S, Curti A, Cavo M, Papayannidis C.
Marconi G, et al. Among authors: sartor c.
Leuk Res. 2021 Feb;101:106497. doi: 10.1016/j.leukres.2020.106497. Epub 2020 Dec 25.
Leuk Res. 2021.
PMID: 33385697
Clinical Trial.